Inflammation and Autoimmunity

Gloved hand holding vial with clear liquid

Our Products

Discover the medicines we’re bringing to patients.

EXPLORE OUR PRODUCTS

Patient Resources

Review information, resources and connections to help you get the most out of your care.

EXPLORE PATIENT RESOURCES

Advancing Innovation in Inflammation and Autoimmunity

Research has shown that the JAK-STAT pathway mediates the cellular effects of cytokines involved in the pathogenesis of many immune-mediated dermatologic conditions.

We are exploring the potential of JAK inhibition across our late-stage pipeline of topical-to-oral and mild-to-severe solutions for chronic immune-mediated dermatologic conditions, such as vitiligo, atopic dermatitis (AD) and hidradenitis suppurativa (HS).

Incyte's JAK Legacy

Voices of Incyte

The development of JAK inhibitors has been transformative in many different conditions. And in particular, inflammatory skin conditions. We’ve had a lot of expertise in the JAK inhibition field, and we’re still learning every day. There’s more that Incyte will continue to do in this space.

- Jim Lee, M.D., Ph.D.

Group Vice President, Head of
Inflammation and Autoimmunity, Delaware

Voices of Incyte

Our work in Inflammation and Autoimmunity is driven by the opportunity to make a meaningful difference for patients. We remain focused on advancing research that can lead to meaningful progress for people living with these conditions.

- Mohamed Issa, Pharm. D., MBA

Executive Vice President and Head
of U.S. Commercial, Delaware

Inflammation and Autoimmunity Focus Areas

Atopic Dermatitis (AD)

AD—the most common type of eczema—is an immune-mediated skin condition that causes irritation and itch. Signs and symptoms of AD include irritated and itchy skin that can cause red lesions that may ooze and crust.¹ Patients with AD are also more susceptible to bacterial, viral and fungal infections.² The clinical signs and symptoms of the disease can have a profound impact on a patient’s quality of life.^3-8

Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo. It affects approximately 0.5% to 2.0% of the population globally.⁹ In the U.S., more than 1.5 million people are diagnosed with vitiligo.¹⁰ The overall prevalence of the condition is estimated to be approximately 2–3 million, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo.^11,12 Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 30.¹³ Vitiligo is associated with quality-of-life impairments and patients are at an increased risk for comorbidities and mental health disorders, including depression.^14,15,16

Hidradenitis Suppurativa (HS)

HS, also known as acne inversa, is an inflammatory skin condition that causes painful bumps to form in the armpit, groin, breast and anal regions of the body.¹⁷ HS typically begins around puberty or in early adulthood and is most prevalent among adults ages 20 to 40.^18,19 Some of the bumps can eventually lead to disfiguring scars. It has a significant impact on daily life and can be debilitating for some patients.¹⁷

REFERENCES